Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney Disease
Top Cited Papers
Open Access
- 15 June 2011
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 305 (23), 2432-2439
- https://doi.org/10.1001/jama.2011.826
Abstract
Fibroblast growth factor 23 (FGF-23) is an endocrine hormone that regulates phosphorus metabolism. Circulating levels of FGF-23 increase progressively as kidney function declines, eventually reaching concentrations in patients with chronic kidney disease that are among the highest in any condition commonly encountered in clinical practice.1 Fibroblast growth factor 23 levels increase in chronic kidney disease as an appropriate physiological adaptation to maintain neutral phosphate balance and normal serum phosphate levels in the setting of reduced renal capacity for phosphate excretion. Preventing increases in serum phosphate is likely beneficial in chronic kidney disease given reports of greater risk of adverse renal and cardiovascular outcomes in association with overt hyperphosphatemia and even modest elevations in serum phosphate within the normal range.2,3 However, small studies suggest that an elevated FGF-23 level is an independent risk factor for mortality among patients undergoing dialysis,4,5 and for more rapid loss of kidney function in earlier stages of chronic kidney disease.6,7 Whether FGF-23 is associated with greater risks of mortality and end-stage renal disease in the much larger population of patients with earlier stages of chronic kidney disease is unknown. We tested the hypothesis that an elevated FGF-23 level is an independent risk factor for death and end-stage renal disease in a large, racially and ethnically diverse, prospective cohort study of individuals with chronic kidney disease stages 2 through 4.Keywords
This publication has 32 references indexed in Scilit:
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney DiseaseJAMA, 2011
- Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort StudyAmerican Journal of Kidney Diseases, 2010
- FGF-23: More than a regulator of renal phosphate handling?Journal of Bone and Mineral Research, 2010
- Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly populationAtherosclerosis, 2009
- Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the communityAtherosclerosis, 2009
- High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patientsNephrology Dialysis Transplantation, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisThe New England Journal of Medicine, 2008
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationThe New England Journal of Medicine, 2004